Skip to content

PressReach

SEARCH icon
  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos
Search

SEARCH FOR AN ARTICLE

  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos

PressReach

icon

      HomeBiotech

      Biotech

      AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
      Biotech

      AbolerIS Pharma Announces First Cohort Dosed in Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis

      May 7, 2025
      Gardin Raises $4.5M to Advance Precision Agriculture with Breakthrough Photosynthesis Sensor & AI Platform to Monitor Greenhouse Crop Health at Scale, in Real Time
      Biotech

      Gardin Raises $4.5M to Advance Precision Agriculture with Breakthrough Photosynthesis Sensor & AI Platform to Monitor Greenhouse Crop Health at Scale, in Real Time

      May 7, 2025
      Wobble Genomics Announces Appointment of Dr. Dietrich A. Stephan as Chairman of the Board of Directors
      Biotech

      Wobble Genomics Announces Appointment of Dr. Dietrich A. Stephan as Chairman of the Board of Directors

      May 6, 2025
      IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
      Biotech

      IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

      May 6, 2025
      IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
      Biotech

      IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

      May 6, 2025
      IND Application for NTS071, Nutshell Therapeutics’ p53 Y220C Allosteric Reactivator, Received US FDA clearance
      Biotech

      IND Application for NTS071, Nutshell Therapeutics’ p53 Y220C Allosteric Reactivator, Received US FDA clearance

      May 4, 2025
      Vector BioMed CEO to Present at ISCT 2025 and Exhibit at ASGCT 2025
      Biotech

      Vector BioMed CEO to Present at ISCT 2025 and Exhibit at ASGCT 2025

      May 3, 2025
      TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
      Biotech

      TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

      May 3, 2025
      Pykus Therapeutics Announces Positive Interim Pilot Clinical Trial Results of PYK-2101, a Novel Retinal Sealant
      Biotech

      Pykus Therapeutics Announces Positive Interim Pilot Clinical Trial Results of PYK-2101, a Novel Retinal Sealant

      May 3, 2025
      Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
      Biotech

      Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

      May 2, 2025
      « 1 … 32 33 34 35 36 … 140 »

       

      LATEST NEWS

      • Health Sanofi Market Potential Boosted by Amvuttra Data

      PressReach

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from PressReach.

      I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

      Market Jar Media Inc. © 2026